Skip to content
All news
Analysis

Primary Health Properties Stock Gets Split Price Target After Analyst Views Diverge

Latest research on Primary Health Properties shows a split among analysts on the price target, with some setting a £1.05 target while others see fair value at £1.15 per share.

June 23, 2026
2 min read
Source: Simply Wall St.
Share:

Key Numbers

price target
£1.05
fair value
£1.15

The latest research on Primary Health Properties (LSE:PHP) centres on a refined £1.05 price target, set against an unchanged fair value estimate of £1.15 per share. Analysts expressing more constructive views see this £1.05 level as consistent with their confidence in the company’s long term profitability assumptions, while more cautious voices question how much upside that target really offers.

Rating Change

No explicit rating change was announced, but the new price target of £1.05 reflects divergent views. More optimistic analysts see the target as aligned with their confidence in long-term profitability, while cautious analysts question the upside potential.

Analyst Rationale

The analysis focuses on long-term profitability assumptions. Bullish analysts believe the £1.05 target represents a reasonable valuation based on future earnings expectations. In contrast, bearish analysts see limited upside compared to the estimated fair value.

Context

No major recent stock performance changes were reported. The stock remains in a tight trading range, with investor focus on the UK healthcare sector. Other analyst opinions were not included in the source.

Conclusion

The price target for Primary Health Properties remains under debate, with a gap between the target and fair value. Investors should monitor upcoming company reports to assess profitability expectations.

Frequently Asked Questions

The new price target is £1.05 per share.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.